EGFR and non-small cell lung carcinoma: With EGFR-TKIs (gefitinib, erlotinib, and afatinib) as first-line treatment for patients carrying sensitizing EGFR mutations with an advanced NSCLC stage, a higher progression-free survival, overall response rate and improved quality of life can be achieved.